"This mezzanine financing enables a significant expansion of the setmelanotide clinical development program, for which the FDA has granted Breakthrough Therapy Designation status for POMC deficiency obesity," said Bart Henderson, President and Founder of Rhythm. "In parallel, we are advancing setmelanotide into initial proof-of-concept studies for several additional rare genetic disorders of obesity that are life-threatening and for which there are no effective treatments."
During 2017, Rhythm plans to initiate Phase 3 registration studies for both POMC and LEPR deficiency obesity, along with Phase 2 proof-of-concept clinical studies for Bardet-Biedl syndrome, Alström syndrome, and POMC heterozygous deficiency obesity. Rhythm is also evaluating setmelanotide for the treatment of Prader-Willi syndrome in a Phase 2 study. The company previously presented clinical data for setmelanotide demonstrating substantial efficacy in reducing weight and hyperphagia in both POMC and LEPR deficiency obesity, rare diseases caused by genetic defects that are upstream of the MC4 receptor.
"We are extremely pleased for the continued support of our investors in this financing," said Keith Gottesdiener, CEO of Rhythm. "The initial proof-of-concept data for setmelanotide in both POMC and LEPR deficiency obesity is compelling and is the foundation for our MC4 genetic obesity program. This mezzanine financing enables both a significant expansion of the clinical program and the build-out of Rhythm's capabilities to support Phase 3 development."
About Setmelanotide (RM-493)
Setmelanotide is a potent, first-in-class MC4R agonist in development for the treatment of obesity caused by genetic deficiencies in the MC4 pathway, a key biological pathway in humans that regulates energy expenditure, homeostasis, and appetite. The critical role of the MC4 pathway in weight regulation was validated with the discovery that single genetic defects along this pathway result in early-onset and severe obesity. In 2016, The New England Journal of Medicine reported results from a setmelanotide Phase 2 trial in pro-opiomelanocortin (POMC) deficiency obesity that demonstrated substantial weight loss in two adult patients. At ObesityWeek 2016, investigators presented initial data for the first patient enrolled in a Phase 2 non-randomized, open-label clinical trial of setmelanotide for the treatment of leptin receptor (LEPR) deficiency obesity. Both POMC and LEPR deficiency obesity are rare genetic disorders associated with severe, early-onset obesity and unrelenting hyperphagia. The initial efficacy data with setmelanotide in these disorders demonstrate that setmelanotide has the potential to provide meaningful efficacy in genetic forms of obesity due to MC4 pathway deficiency by restoring absent LEPR-POMC signaling. The company is currently evaluating setmelanotide for the treatment of six genetic disorders of obesity: POMC and LEPR deficiency obesity, Prader-Willi syndrome, Bardet-Biedl syndrome, Alström syndrome, and POMC heterozygous deficiency obesity.
About Rhythm (www.rhythmtx.com)
Rhythm is a biopharmaceutical company focused on developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. Rhythm's lead peptide product candidate is setmelanotide, a first-in-class melanocortin 4 receptor (MC4R) agonist for the treatment of rare genetic disorders of obesity. Rhythm supports The Genetic Obesity Project (www.GeneticObesity.com), which is dedicated to improving the understanding of severe obesity that is caused by specific genetic defects. The company is based in Boston, Massachusetts.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rhythm-announces-completion-of-41-million-mezzanine-financing-300408672.html
Related biology technology :
1. Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes
2. Rhythm Awarded $1.35 Million from The Michael J. Fox Foundation to Advance Clinical Development of RM-131 for Refractory Constipation in Parkinsons Disease
3. Announcing the new MouseMonitor™ Telemetry and MouseMonitor™ Rhythm Families of Wirelessly Rechargeable Telemetric Implants
4. MediPoint: Cardiac Rhythm Management - US Analysis and Market Forecasts
5. Rhythm Files Registration Statement for Proposed Initial Public Offering
6. Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin
7. Rhythm Appoints Fred T. Fiedorek, M.D., Chief Medical Officer
8. Rhythm Initiates Two Phase 2 Clinical Trials of Setmelanotide (RM-493) in Rare Genetic Disorders of Obesity Caused by MC4 Pathway Deficiencies
9. FDA Office of Orphan Products Development Awards Rhythm $1 Million Grant to Support Phase 2 Study of Setmelanotide in Prader-Willi Syndrome
10. Generex Announces Agreement to Acquire Equity Interest in Alfa Rhythm Ltd.
11. iRhythm Technologies Founder to Present Key Insights Into Digital Health Technology Trends in Cardiac Care at the American Heart Association Scientific Sessions